EyePoint, Inc. (EYPT) shareholders
Close on Nov 17, 2026Market cap $25.51MP/E –Yield –
Ownership
Institutional holdings as of Jun 30, 2026, from 13F filings
Shares held by institutions
Holders of more than 5%
Latest Schedule 13D (active) or 13G (passive) filed by each holder
| Holder | Shares | % of class | Filing | As of |
|---|---|---|---|---|
| JANUS HENDERSON GROUP Ltd. | 9,366,332 | 10.90% | 13G (passive) | Aug 31, 2026 |
| Kevin Tang Joint filing with Tang Capital Management, LLC (9.60%) | 8,250,200 | 9.60% | 13G (passive) | Oct 20, 2026 |
| Cormorant Asset Management, LP Joint filing with Bihua Chen (8.35%) | 7,000,000 | 8.35% | 13G (passive) amendment | Jun 30, 2026 |
| Voting Shares Irrevocable Trust Joint filing with Federated Hermes, Inc. (8.04%), Thomas R. Donahue (8.04%) and 2 more | 6,934,414 | 8.04% | 13G (passive) amendment | Sep 30, 2026 |
| BlackRock, Inc. | 6,430,477 | 7.70% | 13G (passive) amendment | Jun 30, 2026 |
| Phillip Gross Joint filing with Adage Capital Management, L.P. (8.42%), Robert Atchinson (8.42%) | 5,750,000 | 8.42% | 13G (passive) amendment | Dec 31, 2024 |
| Adage Capital Management, L.P. Joint filing with Robert Atchinson (5.71%), Phillip Gross (5.71%) | 4,790,792 | 5.71% | 13G (passive) | Jun 30, 2026 |
| Aaron Cowen Joint filing with Suvretta Capital Management, LLC (9.99%), Averill Master Fund, Ltd. (9.40%) | 4,774,389 | 9.99% | 13G (passive) amendment | Dec 31, 2023 |
| Robert Atchinson Joint filing with Adage Capital Management, L.P. (5.68%), Phillip Gross (5.68%) | 4,700,000 | 5.68% | 13G (passive) amendment | Dec 31, 2025 |
| J. Christopher Donahue Joint filing with Federated Hermes, Inc. (6.68%), Voting Shares Irrevocable Trust (6.68%) and 2 more | 4,599,450 | 6.68% | 13G (passive) amendment | Jun 30, 2025 |
| Adage Capital Partners, L.P. Joint filing with Adage Capital Partners GP, L.L.C. (9.15%), Adage Capital Management, L.P. (9.15%) and 2 more | 4,466,420 | 9.15% | 13G (passive) amendment | Dec 31, 2023 |
| Robert Egen Atkinson Joint filing with Commodore Capital LP (5.10%), Commodore Capital Master LP (5.10%) and 1 more | 4,250,000 | 5.10% | 13G (passive) | May 27, 2026 |
| Paradigm BioCapital Advisors LP Joint filing with Paradigm BioCapital Advisors GP LLC (5.10%), Senai Asefaw, M.D. (5.10%) | 4,192,261 | 5.10% | 13G (passive) | Feb 17, 2026 |
| Franklin Resources, Inc. Joint filing with Franklin Advisers, Inc. (6.00%) | 4,137,567 | 6.10% | 13G (passive) amendment | Dec 31, 2024 |
| Martin P. Sutter Joint filing with Essex Woodlands Fund IX-GP, L.P. (5.00%), Essex Woodlands IX, LLC (5.00%) and 4 more | 2,337,786 | 5.00% | 13D (active) amendment | Dec 4, 2023 |
Top institutional holders
13F holdings as of Jun 30, 2026
| Holder | Shares | % of EYPT | Value | Change | % of portfolio |
|---|---|---|---|---|---|
| Suvretta Capital Management, LLC | 8,296,375 | 9.62% | $118.64M | – | 2.17% |
| BlackRock, Inc. | 7,463,197 | 8.66% | $106.72M | +285,860 | 0.00% |
| Cormorant Asset Management, LP | 7,000,000 | 8.12% | $100.10M | −1,265,000 | 5.13% |
| Federated Hermes, Inc. | 5,681,052 | 6.59% | $81.24M | +11,463 | 0.12% |
| Adage Capital Partners Gp, L.L.C. | 4,827,792 | 5.60% | $69.04M | +1,527,792 | 0.10% |
| Franklin Resources Inc | 4,807,078 | 5.58% | $68.74M | −241,520 | 0.01% |
| Commodore Capital LP | 4,600,000 | 5.34% | $65.78M | +1,775,000 | 3.92% |
| Jupiter Topco LLC | 3,770,381 | 4.37% | $53.90M | New | 0.02% |
| Vanguard Capital Management LLC | 3,630,252 | 4.21% | $51.91M | +70,683 | 0.00% |
| Paradigm Biocapital Advisors LP | 2,890,397 | 3.35% | $41.33M | −252,040 | 0.77% |
| State Street Corp | 2,357,545 | 2.73% | $33.71M | +260,343 | 0.00% |
| Geode Capital Management, LLC | 2,062,390 | 2.39% | $29.50M | +78,725 | 0.00% |
| abrdn plc | 2,008,802 | 2.33% | $28.73M | +270,424 | 0.04% |
| Citadel Advisors LLC | 1,977,610 | 2.29% | $28.28M | +71,735 | 0.00% |
| Balyasny Asset Management L.P. | 1,812,358 | 2.10% | $25.92M | +373,621 | 0.03% |
| Parkman Healthcare Partners LLC | 1,288,163 | 1.49% | $18.42M | −66,637 | 1.89% |
| Eventide Asset Management, LLC | 1,245,583 | 1.44% | $17.81M | – | 0.24% |
| Two Sigma Investments, LP | 1,181,143 | 1.37% | $16.89M | +750,828 | 0.01% |
| Essex Woodlands Management, Inc. | 1,084,857 | 1.26% | $15.51M | – | 6.10% |
| Orbimed Advisors LLC | 1,069,147 | 1.24% | $15.29M | – | 0.28% |
Institutional buying and selling by quarter
Positions opened, added to, reduced and closed by 13F filers
| Quarter | Holders | Shares held | % of shares | New / added | Reduced / closed | Shares bought | Shares sold |
|---|---|---|---|---|---|---|---|
| Q2 2026 | 189 | 93M | 100.0% | 25 / 65 | 60 / 23 | 13M | 7M |
| Q1 2026 | 189 | 90M | 100.0% | 47 / 74 | 40 / 22 | 23M | 11M |
| Q4 2025 | 166 | 84M | 97.0% | 33 / 70 | 36 / 16 | 22M | 8M |
| Q3 2025 | 151 | 70M | 81.1% | 27 / 42 | 48 / 18 | 9M | 8M |
| Q2 2025 | 142 | 69M | 80.2% | 22 / 50 | 37 / 30 | 5M | 10M |
| Q1 2025 | 151 | 74M | 86.0% | 25 / 57 | 45 / 18 | 5M | 5M |
| Q4 2024 | 145 | 74M | 86.3% | 29 / 67 | 25 / 21 | 22M | 6M |
| Q3 2024 | 138 | 59M | 68.3% | 21 / 47 | 49 / 34 | 13M | 9M |
| Q2 2024 | 152 | 59M | 68.2% | 26 / 63 | 46 / 36 | 12M | 11M |
| Q1 2024 | 163 | 58M | 67.2% | 56 / 59 | 35 / 31 | 14M | 7M |
| Q4 2023 | 138 | 52M | 59.8% | 56 / 41 | 29 / 15 | 25M | 7M |
| Q3 2023 | 98 | 34M | 39.1% | 24 / 34 | 19 / 8 | 5M | 3M |
Top mutual fund and ETF holders
Latest monthly portfolio reports (Form N-PORT)
163 funds held EYPT in Q2 2026, 41% of their shares through ETFs. Each fund counts once per quarter, from its quarter-end report.
| Fund | Shares | % of EYPT | Value | % of fund | As of |
|---|---|---|---|---|---|
| Federated Hermes Kaufmann Fund | 2,771,487 | 3.21% | $33.95M | 0.69% | Jul 31, 2026 |
| Vanguard Total Stock Market Index Fund | 2,643,860 | 3.07% | $37.81M | 0.00% | Jun 30, 2026 |
| iShares Russell 2000 ETF | 2,021,128 | 2.34% | $28.90M | 0.03% | Jun 30, 2026 |
| Federated Hermes Kaufmann Small Cap Fund | 1,982,000 | 2.30% | $24.28M | 0.85% | Jul 31, 2026 |
| Eventide Healthcare & Life Sciences Fund | 1,245,583 | 1.44% | $17.81M | 1.00% | Jun 30, 2026 |
| Franklin Biotechnology Discovery Fund | 1,123,495 | 1.30% | $13.76M | 1.19% | Jul 31, 2026 |
| Franklin Small Cap Growth Fund | 1,084,494 | 1.26% | $13.29M | 0.54% | Jul 31, 2026 |
| Vanguard Extended Market Index Fund | 895,912 | 1.04% | $12.81M | 0.01% | Jun 30, 2026 |
| Fidelity Small Cap Index Fund | 846,534 | 0.98% | $10.37M | 0.03% | Jul 31, 2026 |
| iShares Russell 2000 Growth ETF | 607,108 | 0.70% | $8.68M | 0.06% | Jun 30, 2026 |
| State Street(R) SPDR(R) S&P(R) Pharmaceuticals ETF | 530,232 | 0.62% | $7.58M | 1.77% | Jun 30, 2026 |
| Columbia Small Cap Growth Fund | 442,348 | 0.51% | $6.01M | 0.16% | May 31, 2026 |
| Fidelity Extended Market Index Fund | 403,146 | 0.47% | $5.47M | 0.01% | May 31, 2026 |
| Federated Hermes MDT Small Cap Core Fund | 399,795 | 0.46% | $4.90M | 0.22% | Jul 31, 2026 |
| Vanguard Russell 2000 Index Fund | 398,338 | 0.46% | $5.41M | 0.03% | May 31, 2026 |
Officers, directors and major owners
People who filed Forms 3, 4 or 5 in the last two years
| Name | Role | Shares owned | % of shares | Latest filing |
|---|---|---|---|---|
| Jay S. Duker | President and CEO, Director | 187,025 | 0.22% | Jul 14, 2026 |
| George Elston | Chief Financial Officer | 122,470 | 0.14% | Aug 24, 2026 |
| Ramiro Ribeiro | Chief Medical Officer | 4,875 | 0.01% | Jul 2, 2026 |
| Karen L. Zaderej | Director | 49,100 | 0.06% | Aug 18, 2026 |
| Nancy Lurker | Director | 421,235 | 0.49% | Jan 7, 2026 |
| Reginald J. Sanders | Director | – | – | Jan 6, 2026 |
| Wendy F. Dicicco | Director | 9,967 | 0.01% | Jan 6, 2026 |
| John B. Landis | Director | 21,400 | 0.02% | Jan 6, 2026 |
| Stuart Duty | Director | – | – | Jan 6, 2026 |
| Goran Ando | Director | 13,150 | 0.02% | Jan 6, 2026 |
| Fred Hassan | Director | – | – | Jan 6, 2026 |
| Cormorant Asset Management, LP | – | 8,265,000 | 9.59% | Dec 8, 2025 |
| Bihua Chen | – | – | – | Dec 8, 2025 |
| Cormorant Global Healthcare Master Fund, LP | – | 7,288,479 | 8.45% | Dec 8, 2025 |
Insider trades
Common stock transactions reported on Form 4, newest first
| Insider | Date | Transaction | Shares | Price | Value | Shares after |
|---|---|---|---|---|---|---|
| George Elston Chief Financial Officer | Aug 20, 2026 | Gift | +64,953 | – | – | 64,953 |
| George Elston Chief Financial Officer | Aug 20, 2026 | Gift | −64,953 | – | – | 32,517 |
| George Elston Chief Financial Officer | Aug 20, 2026 | Other | +5,000 | – | – | 96,691 |
| George Elston Chief Financial Officer | Aug 20, 2026 | Other | −5,000 | – | – | 25,000 |
| Karen L. Zaderej Director | Aug 18, 2026 | Buy | +10,600 | $4.93 | $52.26K | 49,100 |
| Jay S. Duker President and CEO, Director | Jul 10, 2026 | Tax withholding | −8,059 | $14.72 | $118.63K | 9,594 |
| Jay S. Duker President and CEO, Director | Jul 10, 2026 | Option exercise | +16,667 | – | – | 17,653 |
| Ramiro Ribeiro Chief Medical Officer | Jun 30, 2026 | Option exercise | +2,438 | $8.26 | $20.14K | 4,875 |
| Ramiro Ribeiro Chief Medical Officer | Jun 30, 2026 | Sale(10b5-1 plan) | −2,437 | $15.00 | $36.56K | 2,438 |
| Ramiro Ribeiro Chief Medical Officer | Jun 30, 2026 | Sale(10b5-1 plan) | −2,438 | $15.02 | $36.62K | 0 |
| Ramiro Ribeiro Chief Medical Officer | Jun 30, 2026 | Option exercise | +2,437 | $8.26 | $20.13K | 2,437 |
| George Elston Chief Financial Officer | May 25, 2026 | Tax withholding | −3,627 | $12.93 | $46.90K | 91,691 |
| George Elston Chief Financial Officer | May 25, 2026 | Option exercise | +7,500 | – | – | 95,318 |
| Ramiro Ribeiro Chief Medical Officer | Apr 17, 2026 | Option exercise | +2,437 | $8.26 | $20.13K | 2,437 |
| Ramiro Ribeiro Chief Medical Officer | Apr 17, 2026 | Sale(10b5-1 plan) | −2,437 | $15.00 | $36.56K | 0 |
| Jay S. Duker President and CEO, Director | Mar 23, 2026 | Other | +76,766 | $13.11 | $1.01M | 177,431 |
| Jay S. Duker President and CEO, Director | Mar 23, 2026 | Other | −76,766 | $13.11 | $1.01M | 986 |
| Jay S. Duker President and CEO, Director | Mar 16, 2026 | Buy | +1,500 | $13.15 | $19.73K | 100,665 |
| Ramiro Ribeiro Chief Medical Officer | Mar 4, 2026 | Sale(10b5-1 plan) | −2,438 | $17.87 | $43.57K | 0 |
| Ramiro Ribeiro Chief Medical Officer | Mar 4, 2026 | Option exercise | +2,438 | $8.26 | $20.14K | 2,438 |
| George Elston Chief Financial Officer | Mar 2, 2026 | Gift | −5,000 | – | – | 87,818 |
| George Elston Chief Financial Officer | Mar 2, 2026 | Gift | +5,000 | – | – | 30,000 |
| Ramiro Ribeiro Chief Medical Officer | Feb 17, 2026 | Option exercise | +2,437 | $8.26 | $20.13K | 2,437 |
| Ramiro Ribeiro Chief Medical Officer | Feb 17, 2026 | Sale(10b5-1 plan) | −2,437 | $15.00 | $36.56K | 0 |
| George Elston Chief Financial Officer | Jan 6, 2026 | Option exercise | +15,285 | – | – | 96,339 |
| George Elston Chief Financial Officer | Jan 6, 2026 | Tax withholding | −4,487 | $16.86 | $75.65K | 91,852 |
| Jay S. Duker President and CEO, Director | Jan 6, 2026 | Tax withholding | −10,054 | $16.86 | $169.51K | 77,752 |
| Jay S. Duker President and CEO, Director | Jan 6, 2026 | Option exercise | +20,793 | – | – | 87,806 |
| Nancy Lurker Director | Jan 6, 2026 | Option exercise | +75,133 | – | – | 294,346 |
| Ramiro Ribeiro Chief Medical Officer | Jan 5, 2026 | Sale(10b5-1 plan) | −42,544 | $17.10 | $727.50K | 0 |
| Ramiro Ribeiro Chief Medical Officer | Jan 5, 2026 | Option exercise | +29,250 | $8.26 | $241.61K | 42,544 |
| George Elston Chief Financial Officer | Jan 5, 2026 | Option exercise | +15,000 | – | – | 85,457 |
| George Elston Chief Financial Officer | Jan 5, 2026 | Tax withholding | −4,403 | $17.43 | $76.74K | 81,054 |
| Jay S. Duker President and CEO, Director | Jan 5, 2026 | Tax withholding | −14,505 | $17.43 | $252.82K | 67,013 |
| Jay S. Duker President and CEO, Director | Jan 5, 2026 | Option exercise | +30,000 | – | – | 81,518 |
| Nancy Lurker Director | Jan 5, 2026 | Option exercise | +12,666 | – | – | 219,213 |
| George Elston Chief Financial Officer | Jan 3, 2026 | Option exercise | +19,667 | – | – | 76,781 |
| George Elston Chief Financial Officer | Jan 3, 2026 | Tax withholding | −6,324 | $17.48 | $110.54K | 70,457 |
| Ramiro Ribeiro Chief Medical Officer | Jan 3, 2026 | Option exercise | +19,667 | – | – | 19,667 |
| Ramiro Ribeiro Chief Medical Officer | Jan 3, 2026 | Tax withholding | −6,373 | $17.48 | $111.40K | 13,294 |
| Jay S. Duker President and CEO, Director | Jan 3, 2026 | Tax withholding | −23,447 | $17.48 | $409.85K | 51,518 |
| Jay S. Duker President and CEO, Director | Jan 3, 2026 | Option exercise | +65,000 | – | – | 74,965 |
| George Elston Chief Financial Officer | Dec 19, 2025 | Gift | +5,000 | – | – | 25,000 |
| George Elston Chief Financial Officer | Dec 19, 2025 | Gift | −5,000 | – | – | 57,114 |
| Cormorant Asset Management, LP – | Dec 4, 2025 | Sale | −60,000 | $15.70 | $942.00K | 8,265,000 |
| Nancy Lurker Director | Dec 4, 2025 | Sale(10b5-1 plan) | −9,300 | $15.11 | $140.52K | 206,547 |
| Nancy Lurker Director | Nov 28, 2025 | Sale(10b5-1 plan) | −500 | $14.95 | $7.48K | 215,847 |
| Nancy Lurker Director | Nov 26, 2025 | Sale(10b5-1 plan) | −200 | $14.95 | $2.99K | 216,347 |
| Ramiro Ribeiro Chief Medical Officer | Nov 11, 2025 | Sale(10b5-1 plan) | −2,722 | $11.61 | $31.60K | 0 |
| George Elston Chief Financial Officer | Sep 19, 2025 | Gift | −20,000 | – | – | 62,114 |
| George Elston Chief Financial Officer | Sep 19, 2025 | Gift | +20,000 | – | – | 20,000 |
| Karen L. Zaderej Director | Jul 11, 2025 | Option exercise | +2,000 | – | – | 38,500 |
| Jay S. Duker President and CEO, Director | Jul 10, 2025 | Tax withholding | −7,688 | $11.06 | $85.03K | 9,965 |
| Jay S. Duker President and CEO, Director | Jul 10, 2025 | Option exercise | +16,667 | – | – | 17,653 |
| Nancy Lurker Director | Jul 10, 2025 | Option exercise | +11,111 | – | – | 216,547 |
| Jay S. Duker President and CEO, Director | Jun 23, 2025 | Other | −56,665 | $8.21 | $465.22K | 986 |
| George Elston Chief Financial Officer | May 25, 2025 | Tax withholding | −2,202 | $5.68 | $12.51K | 80,848 |
| George Elston Chief Financial Officer | May 25, 2025 | Option exercise | +7,500 | – | – | 83,050 |
| Karen L. Zaderej Director | May 19, 2025 | Buy | +5,000 | $5.99 | $29.95K | 36,500 |
| Karen L. Zaderej Director | May 16, 2025 | Buy | +5,000 | $5.81 | $29.05K | 31,500 |
Awards, option exercises, tax withholding and gifts are shown alongside open-market buys and sales. Each name links to the filing on SEC EDGAR.
Short interest
Shares sold short and not yet bought back, as of Oct 30, 2026 (FINRA, reported twice a month)
Shares sold short, last 12 months
Short sale volume counts trades marked short on any given day, including market-maker hedging, so it runs far higher than the share of EyePoint's stock actually held short. Settlement fails (shares not delivered on time) peaked at 17,243 shares on Aug 27, 2026 over the last 90 days.
Planned insider sales
Notices of proposed sale filed on Form 144 before shares are sold
| Seller | Filed | Shares | Market value | Planned sale | Acquired through |
|---|---|---|---|---|---|
| Nancy Lurker Officer | Jul 22, 2026 | 1,235 | $15.82K | Jul 22, 2026 | Stock Options |
| Nancy Lurker Director | Jul 22, 2026 | 1,235 | $15.82K | Jul 22, 2026 | Stock Options |
| Nancy Lurker Officer | Jul 21, 2026 | 421,235 | $5.50M | Jul 21, 2026 | Stock Options |
| Ramiro Ribeiro Officer | Apr 17, 2026 | 9,750 | $144.40K | Apr 17, 2026 | Exercise of Stock Options |
| Ramiro Ribeiro Officer | Jan 5, 2026 | 53,792 | $940.28K | Jan 5, 2026 | Exercise of Stock Options |
| Nancy Lurker Officer | Dec 4, 2025 | 9,300 | $140.48K | Dec 4, 2025 | Open Market Purchase/RSU's |
| Nancy Lurker Officer | Nov 28, 2025 | 500 | $7.48K | Nov 28, 2025 | Open Market Purchase/RSU's |
| Nancy Lurker Officer | Nov 26, 2025 | 200 | $2.99K | Nov 26, 2025 | Open Market Purchase/RSU's |
| Ramiro Ribeiro Officer | Nov 12, 2025 | 2,722 | $30.89K | Nov 11, 2025 | Employee Stock Purchase Plan |
| Anthony P. Adamis Director | Oct 23, 2024 | 67,100 | $673.35K | Oct 23, 2024 | Stock Option Exercise |
| David R. Guyer Former Director | Oct 15, 2024 | 36,975 | $329.82K | Oct 14, 2024 | RSU Vesting |
| David R. Guyer Director | May 14, 2024 | 71,850 | $897.41K | May 14, 2024 | RSU Vesting |
| David Scott Jones Officer | Feb 2, 2024 | 10,104 | $288.07K | Feb 2, 2024 | Exercise of Stock Options |
| David Scott Jones Officer | Jan 24, 2024 | 34,442 | $857.95K | Jan 24, 2024 | Exercise of Stock Options |
| Nancy Lurker Director | Jan 24, 2024 | 29,956 | $748.25K | Jan 24, 2024 | Open Market Purchase/RSU's |
See a number that looks wrong?